Blood Cancer J 2021 May 12
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.
Related Questions
New answer by Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty (January 29, 2023)
Unfortunately, optimal treatment after daratumumab failure remains unknown, because most of the phase III trials including pomalidomide/dexamethasone or carfilzomib/dexamethas...